IMARC Group, a leading market research company, has recently released a report titled “Protein Therapeutics Market Report by Product (Monoclonal Antibodies (mAbs), Human Insulin, Erythropoietin, Clotting Factors, Fusion Protein, and Others), Therapy Area (Metabolic Disorders, Immunological Disorders, Hematological Disorders, Cancer, Hormonal Disorders, Genetic Disorders, and Others), Function (Enzymatic and Regulatory Activity, Special Targeting Activity, Vaccines, Protein Diagnostics), and Region 2024-2032”. The study provides a detailed analysis of the industry, including the global protein therapeutics market trends, share, size, and industry trends forecast. The report also includes competitor and regional analysis and highlights the latest advancements in the market.

The global protein therapeutics market size reached US$ 345.6 Billion in 2023. Looking forward, IMARC Group expects the market to reach US$ 603.5 Billion by 2032, exhibiting a growth rate (CAGR) of 6.2% during 2024-2032.

Global Protein Therapeutics Market Trends:

The expanding pipeline of biopharmaceutical companies focusing on rare diseases, where targeted protein-based therapies offer promising treatment options with fewer existing alternatives, addressing significant unmet medical needs in specialized patient populations, is strengthening the market growth.

Additionally, there is an increasing demand for innovative treatments for neurodegenerative diseases where protein-based therapies show potential in targeting disease-specific mechanisms and pathways, offering hope for effective disease modification and symptom management is contributing to the market expansion. Besides this, the rise in global healthcare expenditure and investments in biopharmaceutical research and development (R&D) fosters the discovery and commercialization of novel protein-based drugs that address complex diseases and improve patient outcomes through innovative therapeutic approaches, impelling the market growth.

Request to Get the Sample Report:

https://www.imarcgroup.com/protein-therapeutics-market/requestsample

Factors Affecting the Growth of the Protein Therapeutics Industry:

·         Rising prevalence of chronic diseases:

The rising prevalence of chronic diseases such as cancer, diabetes, and autoimmune disorders is a major driver of the protein therapeutics market. Protein-based drugs offer targeted and specific treatment options for these complex diseases. For instance, monoclonal antibodies (mAbs) have revolutionized cancer treatment by targeting specific antigens on cancer cells, minimizing damage to healthy tissues. Biologics like insulin analogs have transformed diabetes management by providing more stable and effective blood glucose control. As the global burden of chronic diseases continues to rise due to aging populations and changing lifestyles, there is an increasing demand for innovative protein therapeutics that can address unmet medical needs and improve patient outcomes, aiding the market growth.

·         Advancements in biotechnology and protein engineering:

Biotechnological innovations have enabled the development of novel protein therapeutics with enhanced efficacy, reduced side effects, and improved pharmacokinetics. Techniques such as recombinant deoxyribonucleic acid (DNA) technology allow for the production of complex proteins like mAbs in large quantities, ensuring consistent quality and purity. Protein engineering techniques, including rational design and directed evolution, facilitate the optimization of protein structures to improve binding affinity, stability, and specificity. These advancements have expanded the therapeutic potential of proteins beyond traditional drug targets, leading to the development of new biologics and biosimilars across a wide range of therapeutic areas, bolstering the market demand.

·         Personalized medicine:

Personalized medicine aims to tailor treatments to individual patient characteristics, including genetic makeup, biomarker profiles, and disease susceptibility. Protein-based drugs are well-suited for personalized approaches due to their specificity and ability to target specific molecular pathways implicated in diseases. Biomarker-driven therapies, such as HER2-targeted therapies in breast cancer or PD-1 inhibitors in immunotherapy, exemplify how protein therapeutics can be personalized to patient-specific biomarkers for optimized treatment outcomes. The growing understanding of disease mechanisms and advances in diagnostic technologies, such as genomics and proteomics, further support the development and adoption of personalized protein therapeutics supporting the market growth.

Protein Therapeutics Market Report Segmentation:

By Product:

·         Monoclonal Antibodies (mAbs)

·         Human Insulin

·         Erythropoietin

·         Clotting Factors

·         Fusion Protein

·         Others

Monoclonal antibodies (mAbs) represent the largest segment due to their specificity in targeting diseases like cancer and autoimmune disorders with high efficacy and minimal side effects.

By Therapy Area:

·         Metabolic Disorders

·         Immunological Disorders

·         Hematological Disorders

·         Cancer

·         Hormonal Disorders

·         Genetic Disorders

·         Others

Metabolic disorders account for the majority of shares owing to the increasing prevalence of conditions like diabetes and obesity requiring advanced protein-based treatments.

By Function:

·         Enzymatic and Regulatory Activity

·         Special Targeting Activity

·         Vaccines

·         Protein Diagnostics

On the basis of function, the market is segmented into enzymatic and regulatory activity, special targeting activity, vaccines, and protein diagnostics.

Regional Insights:

·         North America

·         Asia Pacific

·         Europe

·         Latin America

·         Middle East and Africa

North America enjoys the leading position due to robust biopharmaceutical research, high healthcare spending, and strong regulatory frameworks supporting protein therapeutics development.

Competitive Landscape with Key Players:

The competitive landscape of the protein therapeutics market size has been studied in the report with the detailed profiles of the key players operating in the market.

Some of These Key Players Include:

·         Amgen Inc.

·         Abbott Laboratories

·         Abbvie Inc.

·         Baxter International Inc.

·         Biogen Inc.

·         Csl Behring L.L.C. (CSL Limited)

·         Eli Lilly and Company

·         F. Hoffmann-La Roche AG (Roche Holding AG)

·         Johnson & Johnson

·         Merck & Co. Inc.

·         Novo Nordisk A/S (Novo Holdings A/S)

·         Pfizer Inc.

Ask Analyst for Customized Report:

https://www.imarcgroup.com/request?type=report&id=2431&flag=C

Key Highlights of the Report:

·         Market Performance (2018-2023)

·         Market Outlook (2024-2032)

·         Market Trends

·         Market Drivers and Success Factors

·         Impact of COVID-19

·         Value Chain Analysis

If you need specific information that is not currently within the scope of the report, we will provide it to you as a part of the customization.

About Us

IMARC Group is a leading market research company that offers management strategy and market research worldwide. We partner with clients in all sectors and regions to identify their highest-value opportunities, address their most critical challenges, and transform their businesses.

IMARC’s information products include major market, scientific, economic and technological developments for business leaders in pharmaceutical, industrial, and high technology organizations. Market forecasts and industry analysis for biotechnology, advanced materials, pharmaceuticals, food and beverage, travel and tourism, nanotechnology and novel processing methods are at the top of the company’s expertise.

Contact Us:

IMARC Group

134 N 4th St

Brooklyn, NY 11249, USA

Website: imarcgroup.com

Email: sales@imarcgroup.com

Americas: +1-631-791-1145 | Europe & Africa: +44-753-713-2163 | Asia: +91-120-433-0800